| Literature DB >> 34574026 |
Imogen Bevan1, Mats Stage Baxter2, Helen R Stagg2, Alice Street1.
Abstract
Testing programs for COVID-19 depend on the voluntary actions of members of the public for their success. Understanding people's knowledge, attitudes, and behavior related to COVID-19 testing is, therefore, key to the design of effective testing programs worldwide. This paper reports on the findings of a rapid scoping review to map the extent, characteristics, and scope of social science research on COVID-19 testing and identifies key themes from the literature. Main findings include the discoveries that people are largely accepting of testing technologies and guidelines and that a sense of social solidarity is a key motivator of testing uptake. The main barriers to accessing and undertaking testing include uncertainty about eligibility and how to access tests, difficulty interpreting symptoms, logistical issues including transport to and from test sites and the discomfort of sample extraction, and concerns about the consequences of a positive result. The review found that existing research was limited in depth and scope. More research employing longitudinal and qualitative methods based in under-resourced settings and examining intersections between testing and experiences of social, political, and economic vulnerability is needed. Last, the findings of this review suggest that testing should be understood as a social process that is inseparable from processes of contact tracing and isolation and is embedded in people's everyday routines, livelihoods and relationships.Entities:
Keywords: COVID-19; isolation; social science; social solidarity; testing
Year: 2021 PMID: 34574026 PMCID: PMC8472251 DOI: 10.3390/diagnostics11091685
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Flow diagram of included studies and reasons for exclusion.
Figure 2Study methods.
Figure 3Geographic regions of data collection.
Figure 4Test type.
Figure 5Data collection periods covered by included studies, by quarter.
Characteristics of included studies.
| Authors | Methods/Site/Setting | Numbers of Participants | Target Population | Type of Test | Data Collection Period | Scope | Publication Stage |
|---|---|---|---|---|---|---|---|
| Methods: Cross-sectional survey Site: Community Setting: North America | 6378 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers | Published | |
| Methods: Longitudinal survey Site: Community Setting: North America | 4759 | National population; Service-users | Molecular | Qr2 2020 | Testing effects | Published | |
| Methods: Focus groups; Interviews; Cross-sectional survey Site: Community Setting: Europe | 37 in focus groups; 25 interviewed; 11711 surveyed | National population | Antibody | Qr2 2020 | Facilitators/Barriers | Published | |
| Methods: Interviews; Cohort study; Cross-sectional survey Site: Institution Setting: North America | 318 surveyed; | Vulnerable group (patient) | Molecular | Qr2 2020 | Testing effects | Published | |
| Methods: Cross-sectional survey; Interviews; Focus groups Site: Institution Setting: Europe | 99 surveyed; | Student and staff group | Antibody; Molecular | Qr4 2020 | Facilitators/Barriers; Testing effects | Published | |
| Methods: Focus groups Site: Institution Setting: Europe | 25 | Student group | Antigen | Qr4 2020 | Facilitators/Barriers | Published | |
| Methods: Longitudinal survey Site: Community Setting: Oceania | 1369 | National population | Molecular | Qr2 2020; Qr3 2020 | Facilitators/Barriers | Preprint | |
| Methods: Interviews Site: Institution Setting: Europe | 15 | Service-users | Molecular | Qr2 2020; Qr3 2020 | Facilitators/Barriers; Testing effects | Published | |
| Methods: Cross-sectional survey Site: Community Setting: North America | 3058 | Geographic sub-population | Molecular | Qr3 2020; Qr4 2020 | Facilitators/Barriers | Preprint | |
| Methods: Cross-sectional survey Site: Community Setting: Asia | 669 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers; Testing effects | Published | |
| Methods: Interviews site: Institution setting: Europe | 18 | Employment group | Antibody; Antigen; Molecular | Qr2 2020 | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Community Setting: North America | 980 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Community Setting: Asia | 147 | National population | Unspecified | Qr3 2020 | Facilitators/Barriers | Preprint | |
| Methods: Case-control survey Site: Community Setting: Africa | 4641 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Institution Setting: Europe | 458 | Student group | Molecular | Unspecified | Facilitators/Barriers | Published | |
| Methods: Case-control survey Site: Community Setting: Europe; North America | 3193 | Service-users; Multi-country | Molecular | Qr1 2020; Qr2 2020; Qr3 2020; Qr4 2020 | Facilitators/Barriers | Preprint | |
| Methods: Cross-sectional survey Site: Institution Setting: North America | 242 | Healthcare workers | Molecular | Qr2 2020 | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Institution Setting: Asia | 297 | Vulnerable group (patient); Healthcare workers | Molecular | Qr2 2020; Qr3 2020 | Testing effects | Published | |
| Methods: Time series of cross-sectional surveys Site: Institution Setting: North America | 270 | Vulnerable group (patient) | Unspecified | Qr2 2020 | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Community Setting: Asia | 664 | Geographic sub-population | Unspecified | Qr4 2020 | Facilitators/Barriers | Published | |
| Methods: Interviews Site: Community Setting: North America | 94 | Vulnerable group | Antigen; Molecular | Qr3 2020; Qr4 2020 | Facilitators/Barriers | Preprint | |
| Methods: Cross-sectional survey Site: Institution; Community Setting: Asia | 1167 | National population; Healthcare workers | Molecular; Antibody; Antigen | Qr2 2020; Qr3 2020 | Facilitators/Barriers; Testing effects | Published | |
| Methods: Focus groups Site: Community Setting: Europe | 60 | National population | Antibody | Qr2 2020 | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Community Setting: North America | 979 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers; Testing effects | Published | |
| Methods: Cross-sectional survey Site: Institution Setting: Europe | 200 | Employment group | Antibody | Qr2 2020 | Testing effects | Published | |
| Methods: Cross-sectional survey Site: Community Setting: Europe | 524 | Service-users | Antigen; Molecular | Qr4 2020; Qr1 2021 | Testing effects | Published | |
| Methods: Cross-sectional survey Site: Community Setting: North America | 1221 | Geographic sub-population | Molecular | Qr3 2020 | Facilitators/Barriers | Published | |
| Methods: Case-control survey Site: Community Setting: Asia | 222 | Vulnerable group | Unspecified | Qr3 2020; Qr4 2020 | Facilitators/Barriers | Published | |
| Methods: Interview Site: Institution Setting: Europe | 15 | Healthcare workers | Unspecified | Qr1 2020; Qr2 2020 | Facilitators/Barriers; Testing effects | Published | |
| Methods: Cross-sectional survey Site: Community Setting: Africa | 524 | National population | Unspecified | Unspecified | Facilitators/Barriers | Preprint | |
| Methods: Cross-sectional survey Site: Community Setting: South America | 1656 | National population | Antibody; Antigen; Molecular | Qr3 2020 | Facilitators/Barriers | Published | |
| Methods: Cohort study; Cross-sectional survey Site: Institution Setting: North America | 2180 | Student group | Molecular | Qr2 2020; Qr3 2020 | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Community Setting: North America | 178 | Age-based sub- population | Unspecified | Qr3 2020 | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Community Setting: Oceania | 1846 | Patient group | Molecular | Qr1 2020 | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Community Setting: North America | 1435 | National population | Unspecified | Qr1 2020 | Facilitators/Barriers | Published | |
| Methods: Time series of cross-sectional surveys Site: Community Setting: Europe | 53880 | National population | Antigen; Molecular | Qr1 2020; Qr2 2020; Qr3 2020; Qr4 2020 | Testing effects | Published | |
| Methods: Cross-sectional survey Site: Community Setting: North America | 897 | National population | Unspecified | Unspecified | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Community Setting: South America | 5504 | Multi-country | Unspecified | Qr1 2020; Qr2 2020 | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Community Setting: North America | 148 | National population | Antibody; Molecular | Unspecified | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Community Setting: Europe | 778 | National population | Unspecified | Qr2 2020 | Facilitators/Barriers | Preprint | |
| Methods: Cross-sectional survey Site: Community Setting: Europe | 96 | Geographic sub-population | Molecular | Qr1 2020 | Testing effects | Published | |
| Methods: Interviews; Cross-sectional survey Site: Institution Setting: Europe | 18 interviewed; | Students and staff group; Service-users | Antigen | Qr4 2020; Qr1 2021 | Testing effects | Preprint | |
| Methods: Interviews; Focus groups Site: Community Setting: Europe | 223 | Geographic sub-population; Staff and student group | Molecular (RT-LAMP) | Qr2 2020; Qr3 2020; Qr4 2020 | Testing effects | Preprint | |
| Methods: Cross-sectional survey Site: Community Setting: North America | 1421 | Health service users | Molecular | Unspecified | Facilitators/Barriers | Published | |
| Methods: Cross-sectional survey Site: Community Setting: North America | 4240 | National population | Molecular | Qr2 2020 | Facilitators/Barriers | Published | |
| Methods: Case-control survey Site: Community Setting: North America | 1194 | National population | Unspecified | Qr3 2020 | Testing effects | Preprint | |
| Methods: Discrete choice experiment Site: Community Setting: North | 4793 | National population | Antibody; Antigen; Molecular | Qr3 2020 | Facilitators/Barriers | Published |
Figure 6Themes.
Acceptability, uptake, and barriers to testing.
| Themes | Findings | Studies |
|---|---|---|
|
| General public has knowledge of main COVID-19 symptoms and/or testing types, uses, and accuracy. | Lan et al. (National pop/Healthcare workers China) |
| Patient interpretation of severity, type, and number of symptoms influences test-seeking behavior. Misrecognition or misattribution of symptoms to other causes is a barrier to testing. | Clipman et al. (Geographic sub pop, US) | |
|
| To protect family, colleagues, and others in the community by reducing the spread of COVID-19. | Blake et al. (1) (Student and staff group, UK) |
| To be informed of one’s disease status. | Clipman et al. (Geographic sub pop, US) | |
| To contribute to scientific research and public management of the pandemic. | Blake et al. (1) (Student and staff group, UK) | |
|
| Logistical issues, including not knowing where to go to get tested, lacking transport, perceptions of long waiting times, or test turnaround times are barriers to testing. | Clipman et al. (Geographic sub pop, US) |
| COVID-19 self-test kits with different sample extraction methods (cheek swab or spit, pharyngeal swab, nasopharyngeal swab, fingerprick, DBS) are deemed usable and acceptable. | Atchison et al. (National pop, UK) | |
| People experience physical discomfort when using COVID-19 tests, in particular nasopharyngeal sampling methods. | Hofschulte-Beck et al. (Healthcare workers, US) | |
| A wide variety of test sites (school/university, workplace, drive-thru, mobile testing services, home testing) are found to be convenient. Perceived convenience of testing site encourages uptake. | Blake et al. (2) (Student group, UK) | |
|
| Concerns about how employers, colleagues, or peers will react, or widespread disease stigma in some settings, are barriers to testing. | De Camargo (Employment group, UK) |
| Endorsement from employers, educational institutions, peers, and/or colleagues encourages testing. | Blake et al. (1) (Student and staff group, UK) | |
|
| No association between socioeconomic variables and people’s willingness to test. | Thunstrom et al. (National pop, US) |
| Perceptions of test affordability, costs of accessing testing, and/or costs associated with self-isolation are barriers to testing. | Ali et al. (National pop, US) | |
|
| Lack of trust in government bodies to deliver and manage testing is a barrier to testing in some sub-populations. | Ferree et al. (National pop, Malawi) |
| The accuracy and reliability of tests are a concern for some people, and in some instances, affect willingness to test. | Knight et al. (Vulnerable group, US) | |
|
| Vulnerabilities relating to health, socioeconomic status, housing, or political status can prevent people from engaging with testing services. | Bender et al. (Vulnerable patient group, US) |
Impacts of testing.
| Themes | Findings | Studies |
|---|---|---|
|
| Testing is perceived as helpful for managing anxiety or fear. Receiving a negative test result is especially reassuring for individuals. | Dai et al. (National pop, Malaysia) |
| Perceptions of testing as unavailable have negative effects on mental health. | Dai et al. (National pop, Malaysia) | |
|
| People report high levels of adherence to guidelines on protective behaviors and/or express intentions to self-isolate should they receive a positive test result. | Christensen et al. (Service-users, Denmark) |
| Some people find guidelines on self-isolation following a positive test result unclear or are practically unable to comply with these due to living arrangements or work. | Allen et al. (National pop/service-users, US) | |
| People report that they would not change their behavior or intend to do so following a negative test (or positive in the case of an antibody test result). | Lecouturier et al. (National pop, UK) | |
| Some people report engaging in riskier behaviors or intending to do so following a negative test result. | Martin et al. (National pop, UK) |